<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624819</url>
  </required_header>
  <id_info>
    <org_study_id>111345 (Mth 12)</org_study_id>
    <secondary_id>111346 (Mth 24)</secondary_id>
    <secondary_id>111347 (Mth 48)</secondary_id>
    <nct_id>NCT00624819</nct_id>
  </id_info>
  <brief_title>Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine</brief_title>
  <official_title>Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This protocol posting deals with objectives &amp; outcome measures of the extension phase up to
      48-50 months post booster vaccination, to assess long-term antibody persistence in children
      at around 30, 42 and 66 months of age, who received previously 4 doses of pneumococcal
      conjugate vaccine. The objectives &amp; outcome measures of the primary phase are presented in a
      separate protocol posting (NCT number = 00307554). This Protocol posting has been updated in
      order to comply with the FDA AA (Sep 2007).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists in a serological follow-up study to evaluate persistence 12, 24 and 48
      months after the booster vaccination study (107046). No study vaccines will be administered
      within this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pneumococcal antibody concentrations against vaccine containing serotypes ≥ 0.05 µg/mL at around 1, 2 and 4 years post booster</measure>
    <time_frame>At 1, 2 and 4 years post booster vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal antibody concentrations against vaccine containing serotypes</measure>
    <time_frame>At 1, 2 and 4 years post booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic activity against vaccine containing pneumococcal serotypes</measure>
    <time_frame>At 1, 2 and 4 years post-booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against pneumococcal crossreactive serotypes 6A and 19A</measure>
    <time_frame>At 1, 2 and 4 years post-booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A</measure>
    <time_frame>At 1, 2 and 4 years post-booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against protein D</measure>
    <time_frame>At 1, 2 and 4 years post-booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status</measure>
    <time_frame>At 1, 2 and 4 years post-booster vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse event related to study procedures, previous study vaccination or non-participation at a defined visit</measure>
    <time_frame>Throughout the entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">524</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>10Pn-10Pn Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects having received four doses of GlaxoSmithKline Biological's 10-valent pneumococcal conjugate vaccine (GSK1024850A) in primary vaccination study and in booster vaccination study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7Pn-7Pn Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects having received four doses of Prevenar vaccine in primary vaccination study and in booster vaccination study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7Pn-10Pn Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects having received three doses of Prevenar in primary vaccination study and one dose of GSK1024850A vaccine in booster vaccination study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK1024805A</intervention_name>
    <description>No vaccination in this trial</description>
    <arm_group_label>7Pn-10Pn Group</arm_group_label>
    <arm_group_label>10Pn-10Pn Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>No vaccination in this trial</description>
    <arm_group_label>7Pn-10Pn Group</arm_group_label>
    <arm_group_label>7Pn-7Pn Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between, and including, 28-30 months of age at the time of first blood
             sampling.

          -  Subjects who previously participated in the 105553 and 107046 studies and who received
             a full four dose regimen of pneumococcal conjugate vaccine during the primary and
             booster studies.

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  Written informed consent, covering visits 1, 2 and 3, obtained from the parent or
             guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

        Exclusion Criteria:

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within 6
             months prior to the blood sampling

          -  Administration of any additional pneumococcal vaccine since end of 107046 study.

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the blood sampling.

          -  Administration of immunoglobulins and/or any blood products less than 6 months prior
             to blood sampling.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition since the
             end of the 107046 study, based on medical history and physical examination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Months</minimum_age>
    <maximum_age>32 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olesnica</city>
        <zip>56-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <disposition_first_submitted>July 24, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 2, 2012</disposition_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Haemophilus influenzae</keyword>
  <keyword>Pneumococcal conjugate vaccine</keyword>
  <keyword>Antibody persistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111345 (Mth 12)</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111345 (Mth 12)</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111345 (Mth 12)</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111345 (Mth 12)</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111345 (Mth 12)</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111345 (Mth 12)</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>August 25, 2017</submitted>
    <returned>April 5, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

